Email

Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today

Dated July 24, 2015 Ref IMAGES-008-HOUSE_OVERSIGHT_026362.txt Release House Oversight Committee — Epstein Estate Records (Nov 2025) 1 pages

Epstein Suite indexes the text; the original document lives at its official source. We don't host the original file — view it on the official release to read it in full.

View the original on the official release

People & organizations named in this document

Being named here is not an accusation of wrongdoing.

Document text

Text is machine OCR and may contain errors. Confirm against the original source above.

From: jeffrey E. [[email protected]] Sent: 7/24/2015 8:47:39 PM To: Sultan Bin Sulayern Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today yes, it requires a shot, its not a pill and so far no long term effects known On Fri, Jul 24, 2015 at 4:37 PM, Sultan Bin Sulayem <q wrote: Have you heard of this colestrol Jul 24, 2015 @ 3:23 PM 1,169 views The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot Matthew Herper , Forbes Staff I cover science and medicine, and believe this is biology's century. e Follow on Forbes (1970) ° Full Bio ° Recent Posts ° Popular Posts I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins. It might be a big step in the battle against heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost HOUSE_OVERSIGHT_026362

Have a question about what this document contains?

Ask the documents